CN103108866B - 环己烷衍生物化合物 - Google Patents

环己烷衍生物化合物 Download PDF

Info

Publication number
CN103108866B
CN103108866B CN201180046082.8A CN201180046082A CN103108866B CN 103108866 B CN103108866 B CN 103108866B CN 201180046082 A CN201180046082 A CN 201180046082A CN 103108866 B CN103108866 B CN 103108866B
Authority
CN
China
Prior art keywords
methyl
group
trans
mmol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180046082.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN103108866A (zh
Inventor
户田成洋
高野理惠子
志田健
片桐隆广
岩本充广
芦田真二
山崎真美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of CN103108866A publication Critical patent/CN103108866A/zh
Application granted granted Critical
Publication of CN103108866B publication Critical patent/CN103108866B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201180046082.8A 2010-09-27 2011-09-26 环己烷衍生物化合物 Expired - Fee Related CN103108866B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010215403 2010-09-27
JP2010-215403 2010-09-27
PCT/JP2011/071830 WO2012043445A1 (ja) 2010-09-27 2011-09-26 シクロヘキサン誘導体化合物

Publications (2)

Publication Number Publication Date
CN103108866A CN103108866A (zh) 2013-05-15
CN103108866B true CN103108866B (zh) 2015-09-09

Family

ID=45892891

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180046082.8A Expired - Fee Related CN103108866B (zh) 2010-09-27 2011-09-26 环己烷衍生物化合物

Country Status (29)

Country Link
US (3) US8710060B2 (enExample)
EP (1) EP2623492B1 (enExample)
JP (1) JP5753179B2 (enExample)
KR (1) KR20130109124A (enExample)
CN (1) CN103108866B (enExample)
AU (1) AU2011309212B2 (enExample)
BR (1) BR112013007145A2 (enExample)
CA (1) CA2812898C (enExample)
CO (1) CO6690804A2 (enExample)
CY (1) CY1115450T1 (enExample)
DK (1) DK2623492T3 (enExample)
ES (1) ES2478518T3 (enExample)
HR (1) HRP20140720T1 (enExample)
IL (1) IL225440A (enExample)
IN (1) IN2013MN00506A (enExample)
MX (1) MX2013003219A (enExample)
MY (1) MY157542A (enExample)
NZ (1) NZ609596A (enExample)
PH (1) PH12013500583A1 (enExample)
PL (1) PL2623492T3 (enExample)
PT (1) PT2623492E (enExample)
RS (1) RS53447B (enExample)
RU (1) RU2013119603A (enExample)
SG (1) SG188415A1 (enExample)
SI (1) SI2623492T1 (enExample)
SM (1) SMT201400109B (enExample)
TW (1) TWI501953B (enExample)
WO (1) WO2012043445A1 (enExample)
ZA (1) ZA201301652B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012043445A1 (ja) * 2010-09-27 2012-04-05 第一三共株式会社 シクロヘキサン誘導体化合物
US10973439B2 (en) 2016-12-29 2021-04-13 BioMech Sensor LLC Systems and methods for real-time data quantification, acquisition, analysis, and feedback
US9773330B1 (en) 2016-12-29 2017-09-26 BioMech Sensor LLC Systems and methods for real-time data quantification, acquisition, analysis, and feedback
US10352962B2 (en) 2016-12-29 2019-07-16 BioMech Sensor LLC Systems and methods for real-time data quantification, acquisition, analysis and feedback
US11318350B2 (en) 2016-12-29 2022-05-03 BioMech Sensor LLC Systems and methods for real-time data quantification, acquisition, analysis, and feedback

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440390A (zh) * 2000-05-05 2003-09-03 奥索-麦克尼尔药品公司 用作促胃动素拮抗剂的新的取代二胺衍生物
WO2005027637A1 (en) * 2003-09-17 2005-03-31 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
WO2007144400A1 (en) * 2006-06-15 2007-12-21 Glaxo Group Limited Benzylpiperazine derivatives as motilin receptor antagonists
CN101258143A (zh) * 2005-07-26 2008-09-03 葛兰素集团有限公司 苄基哌嗪衍生物及其医学用途
WO2009068552A1 (en) * 2007-11-28 2009-06-04 Glaxo Group Limited Piperazinyl-sulfonamide derivatives useful in the treatment of gpr38 receptor mediated diseases
CN101511791A (zh) * 2006-06-28 2009-08-19 葛兰素集团有限公司 用于治疗gpr38受体介导的疾病的哌嗪基衍生物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20090031688A (ko) 2006-06-28 2009-03-27 글락소 그룹 리미티드 Ｇｐｒ３８ 수용체 매개 질환의 치료에 유용한 피페라지닐 유도체
WO2012043445A1 (ja) * 2010-09-27 2012-04-05 第一三共株式会社 シクロヘキサン誘導体化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1440390A (zh) * 2000-05-05 2003-09-03 奥索-麦克尼尔药品公司 用作促胃动素拮抗剂的新的取代二胺衍生物
WO2005027637A1 (en) * 2003-09-17 2005-03-31 Bristol-Myers Squibb Company Compounds useful as motilin agonists and method
CN101258143A (zh) * 2005-07-26 2008-09-03 葛兰素集团有限公司 苄基哌嗪衍生物及其医学用途
WO2007144400A1 (en) * 2006-06-15 2007-12-21 Glaxo Group Limited Benzylpiperazine derivatives as motilin receptor antagonists
CN101511791A (zh) * 2006-06-28 2009-08-19 葛兰素集团有限公司 用于治疗gpr38受体介导的疾病的哌嗪基衍生物
WO2009068552A1 (en) * 2007-11-28 2009-06-04 Glaxo Group Limited Piperazinyl-sulfonamide derivatives useful in the treatment of gpr38 receptor mediated diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
人胃动素受体基因表达载体的构建;王志刚,等;《中华实验外科杂志》;20030908;第20卷(第09期);第789-791页 *
胃动素受体基因SNP位点的筛选及其与糖尿病胃轻瘫的关系;王志刚,等;《中国糖尿病杂志》;20060418;第14卷(第02期);第101-102页 *

Also Published As

Publication number Publication date
HK1185081A1 (en) 2014-02-07
AU2011309212B2 (en) 2014-06-19
EP2623492A4 (en) 2013-09-25
CN103108866A (zh) 2013-05-15
EP2623492A1 (en) 2013-08-07
US20130289048A1 (en) 2013-10-31
ES2478518T3 (es) 2014-07-22
US20140221391A1 (en) 2014-08-07
US20140221392A1 (en) 2014-08-07
US8710060B2 (en) 2014-04-29
CO6690804A2 (es) 2013-06-17
BR112013007145A2 (pt) 2016-06-14
SMT201400109B (it) 2014-09-08
MX2013003219A (es) 2013-06-18
EP2623492B1 (en) 2014-05-14
CA2812898A1 (en) 2012-04-05
US9051255B2 (en) 2015-06-09
AU2011309212A1 (en) 2013-03-21
CY1115450T1 (el) 2017-01-04
PT2623492E (pt) 2014-08-29
RU2013119603A (ru) 2014-11-10
TWI501953B (zh) 2015-10-01
MY157542A (en) 2016-06-15
NZ609596A (en) 2013-12-20
PL2623492T3 (pl) 2014-09-30
IL225440A0 (en) 2013-06-27
IL225440A (en) 2015-11-30
JP5753179B2 (ja) 2015-07-22
JPWO2012043445A1 (ja) 2014-02-06
SI2623492T1 (sl) 2014-09-30
HRP20140720T1 (hr) 2014-08-29
RS53447B (sr) 2014-12-31
IN2013MN00506A (enExample) 2015-05-29
TW201217342A (en) 2012-05-01
ZA201301652B (en) 2014-04-30
DK2623492T3 (da) 2014-08-11
SG188415A1 (en) 2013-04-30
KR20130109124A (ko) 2013-10-07
CA2812898C (en) 2015-11-17
PH12013500583A1 (en) 2013-05-20
WO2012043445A1 (ja) 2012-04-05

Similar Documents

Publication Publication Date Title
JP6301842B2 (ja) 複素環アミド誘導体及びそれを含有する医薬
CA2787248C (en) Piperazine compound having a pgds inhibitory effect
BRPI0618417A2 (pt) novos ligandos de receptores de vanilàide e seu uso para produzir medicamentos
EA021367B1 (ru) Производное пиридин-3-карбоксамида
CN103108866B (zh) 环己烷衍生物化合物
US9815803B2 (en) Process for the preparation of substituted cycloserines
JP2022519301A (ja) Ｎ－（ピリジン－２－イル）ピリジン－スルホンアミド誘導体及び疾患の処置におけるそれらの使用
JP2021528477A (ja) 節足動物を制御するための新規化合物
CN101268046B (zh) 作为毒蕈碱性受体拮抗剂的碳酰胺衍生物
KR100956703B1 (ko) 간 카르니틴 팔미토일 전이효소(ｌ-ｃｐｔ1) 저해제로서유용한 설폰아마이드 유도체
KR20070047338A (ko) 4-아미노메틸 벤즈아미딘 유도체 및 그의 ⅶａ 인자억제제로서의 용도
NZ589934A (en) Piperidine biphenyl carbamic acid compounds active as muscarinic receptor antagonists
MX2014003386A (es) Derivados de metansulfonamida sustituidos con amina como ligandos del receptor de vanilloide.
HK1185081B (en) Cyclohexane derivative compound
CA2603030C (en) Benzyloxypropylamine derivative
JP2012067054A (ja) スルホンアミド誘導体化合物
DE10065434A1 (de) Indole
HK1117163B (en) Carboxamide derivatives as muscarinic receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20150909

Termination date: 20170926

CF01 Termination of patent right due to non-payment of annual fee